Stockscreener 앱 받기
4.33
0.92%
-0.04
시장 영업 전:
4.54
0.21
+4.85%
전일 마감가:
$4.37
열려 있는:
$4.34
하루 거래량:
506.63K
Relative Volume:
0.76
시가총액:
$254.26M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
82.63
EPS:
0.0524
순현금흐름:
$12.42M
1주 성능:
+6.13%
1개월 성능:
-14.76%
6개월 성능:
-8.55%
1년 성능:
-17.37%
1일 변동 폭
$4.31
$4.40
1주일 범위
$3.95
$4.46
52주 변동 폭
$3.85
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.33 | 254.26M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-31 | 개시 | H.C. Wainwright | Buy |
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Capitals Announce ALL CAPS 2025 Playoffs Initiatives Presented by Vanda Pharmaceuticals Inc. - NHL.com
FDA Drug Rules Under Fire in Pharma Free Speech Fight - Law360
Vanda Sues FDA To Block Off-Label Use Drug Promo Regs - Law360
Vanda Pharmaceuticals: Financials Are Great, But Market Reaction Is Confusing (VNDA) - Seeking Alpha
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting - Nasdaq
Class Action Update Vanda Pharmaceuticals Inc. (VNDA) & Stamps.com Inc. (STMP)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Class Action Update Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Class Action Notice Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
High Growth Tech Stocks In US With Promising Potential - simplywall.st
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals - Benzinga
Vanda Pharmaceuticals Seeks US FDA Approval for Bysanti to Treat Schizophrenia, Acute Bipolar I Disorder - MarketScreener
Vanda Pharmaceuticals submits NDA to FDA for Bysanti - TipRanks
Vanda seeks FDA nod for new bipolar, schizophrenia drug - Investing.com
Vanda seeks FDA nod for new bipolar, schizophrenia drug By Investing.com - Investing.com UK
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - PR Newswire
HC Wainwright maintains $20 target on Vanda Pharmaceuticals stock By Investing.com - Investing.com UK
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate - MarketScreener
Vanda Pharmaceuticals announces FDA review date for new drug By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals announces FDA review date for new drug - Investing.com
Vanda Pharmaceuticals’ New Drug Application Accepted by FDA - TipRanks
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - GuruFocus.com
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus.com
Insider Buying: Mihael Polymeropoulos Acquires 10,000 Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus.com
CLASS ACTION UPDATE for VNDA, CTL and INGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
CLASS ACTION UPDATE for AVEO, KHC and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires $50,200.00 in Stock - MarketBeat
Vanda Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Vanda Pharmaceuticals CEO Mihael Polymeropoulos buys $50,150 in stock By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals CEO Mihael Polymeropoulos buys $50,150 in stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $50,150 worth of shares (10,000 units at $5.01), increasing direct ownership by 0.44% to 2,295,731 units (SEC Form 4) - Quantisnow
CLASS ACTION UPDATE for AVEO, DPLO and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Vanda Pharmaceuticals CEO Mihael Polymeropoulos acquires $50,200 in stock By Investing.com - Investing.com India
US FDA Spikes Vanda’s Hetlioz For Insomnia, Lack Of Well-Controlled Trial ‘Fatal’ - Citeline News & Insights
Vanda Pharmaceuticals CEO Mihael Polymeropoulos acquires $50,200 in stock - Investing.com
President and CEO Polymeropoulos Mihael Hristos bought $50,200 worth of shares (10,000 units at $5.02), increasing direct ownership by 0.44% to 2,285,731 units (SEC Form 4) - Quantisnow
President and CEO Polymeropoulos Mihael Hristos covered exercise/tax liability with 95,999 shares and bought $47,050 worth of shares (10,000 units at $4.71), decreasing direct ownership by 4% to 2,275,731 units (SEC Form 4) - Quantisnow
CLASS ACTION UPDATE for TYME, GE and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
Allspring Global Investments Holdings LLC Sells 77,738 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Purchases 10,000 Shares - MarketBeat
Vanda Pharmaceuticals CEO acquires $47,600 in common stock By Investing.com - Investing.com Australia
Vanda Pharmaceuticals CEO acquires $47,600 in common stock - Investing.com India
President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,361,730 units (SEC Form 4) - Quantisnow
US High Growth Tech Stocks With Strong Potential - Yahoo Finance UK
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
February 2025 Penny Stocks To Keep An Eye On - Simply Wall St
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
자본화:
|
볼륨(24시간):